Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 02, 2026
Albemarle (ALB) Stock Drops -23.75% Over 30 Days as Lithium Pressures Persist

Albemarle (ALB) Stock Drops -23.75% Over 30 Days as Lithium Pressures Persist

Key Takeaways

  • Albemarle (ALB) shares fell roughly 23.75% over the last 30 days, declining from $137.75 on September 2 to $105.03 by October 1.
  • The broader quarterly trend has also been negative, with the stock down approximately 22.5% over the trailing three-month period.
  • Persistent weakness in lithium prices and concerns about market oversupply have remained the dominant pressures on lithium producers.
  • Investor sentiment has stayed cautious amid questions over electric-vehicle (EV) demand growth and inventory destocking across the battery supply chain.

Albemarle's Role in the Lithium Sector

Albemarle Corporation is a Charlotte, North Carolina-based specialty chemicals company and one of the world's largest lithium producers. The company operates across three core segments: Energy Storage, which supplies lithium hydroxide, lithium carbonate, and related products used in EV batteries and energy storage systems; Specialties, which includes bromine and other performance chemicals; and Ketjen, which provides catalysts for the refining and petrochemical industries.

Albemarle's lithium operations span major global resources, including the Salar de Atacama in Chile, the Greenbushes and Wodgina assets in Australia, and facilities in the United States. Because lithium is central to the electrification of transportation, investors closely track ALB as a key barometer for the battery materials market. The stock tends to be highly sensitive to lithium spot prices, supply-demand balances, and the pace of EV adoption. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ALB Stock Performance: 30-Day and Quarterly Moves

Over the last 30 days, Albemarle shares declined from $137.75 on September 2 to $105.03 at the close on October 1, a move of approximately -23.75%. The decline was broad-based rather than a single-session event, with the stock trending lower through most of September as selling pressure persisted.

The quarterly picture tells a similar story. Measured from roughly $135.56 in early July, the stock has fallen about 22.5% over the trailing three-month period. After a mid-August rebound that briefly carried shares above $143, the stock reversed sharply in September, giving back those gains and then some. The overall trend across both timeframes has been decidedly negative, reflecting sustained caution around the lithium market rather than isolated volatility.

Factors Behind the Recent 30-Day Decline

The most important factor behind Albemarle's recent decline has been the continued weakness in the lithium market. Lithium carbonate and hydroxide prices have remained under pressure as new supply additions from global projects continued to outpace near-term demand, keeping the market in a state of oversupply. For a producer as leveraged to lithium pricing as Albemarle, soft spot prices directly weigh on revenue expectations and investor sentiment.

Alongside pricing pressures, investor concerns about the pace of EV adoption and downstream inventory destocking have added to the selling. Battery manufacturers and cathode producers have been working through existing lithium inventories, which reduces near-term purchasing activity and clouds the demand outlook. Macroeconomic uncertainty and broader risk-off positioning in cyclical and commodity-linked equities also contributed to the downward momentum during the period.

Institutional activity reflected the cautious tone, with the stock experiencing elevated trading volumes on several down days in September, a pattern consistent with broad-based repositioning rather than a single catalyst-driven selloff.

Quarterly Drivers and the Broader Lithium Narrative

The quarterly decline extends a longer narrative of pressure on lithium producers. Over the trailing three months, Albemarle's stock has moved lower as the market continued to digest a supply glut that emerged after years of aggressive capacity expansion across Australia, Chile, Argentina, and Africa. Even as some higher-cost producers have signaled curtailments, aggregate supply has remained sufficient to keep prices subdued.

Demand, while still growing in absolute terms, has not grown quickly enough to absorb the added supply. Slower-than-anticipated EV sales growth in certain regions and ongoing cost-cutting across the battery value chain have reinforced a cautious outlook. The mid-August bounce in Albemarle shares proved short-lived, and the subsequent September selloff illustrates how quickly sentiment can shift when spot pricing fails to confirm a durable recovery. For investors, the quarter has been defined by a search for tangible evidence that the lithium market is rebalancing. From what I see, this remains a key area to monitor closely.

Key Factors to Watch for ALB Going Forward

Several factors will likely shape Albemarle's trajectory in the months ahead. First, lithium spot prices remain the single most important variable, and any sign of a sustained pricing recovery could shift sentiment quickly. Investors will also monitor quarterly earnings and, more importantly, management commentary on volume guidance, cost discipline, and capital spending, since Albemarle has previously adjusted its investment plans in response to market conditions.

On the supply side, announcements of project curtailments, delays, or mine closures by higher-cost producers could signal that the market is moving toward balance. On the demand side, EV sales data, battery inventory levels, and government policies around electrification and critical minerals will be closely watched. Broader macroeconomic conditions, including interest rates and industrial activity, may also influence commodity-linked equities. As always, these are considerations to monitor rather than a basis for any specific investment decision. I’m watching this closely with the help of Tickeron’s AI Trend Prediction Engine to gauge potential shifts.

Using AI Tools for Market Analysis

When evaluating volatile names like Albemarle, I find it helpful to review automated trading strategies through Tickeron’s Trending AI Robots page. It offers a curated view of high-performing bots across different strategies and timeframes, allowing for a more systematic look at data-driven approaches without reviewing the entire catalog. This has become a practical part of my research process for identifying active opportunities in challenging sectors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ALB in downward trend: price dove below 50-day moving average on September 09, 2026

ALB moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALB as a result. In 64 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for ALB turned negative on September 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

The 10-day moving average for ALB crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ALB entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALB's RSI Indicator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALB advanced for three days, in 247 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

ALB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ALB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.576) is normal, around the industry mean (6.363). P/E Ratio (397.741) is within average values for comparable stocks, (209.940). Projected Growth (PEG Ratio) (0.959) is also within normal values, averaging (1.548). Dividend Yield (0.015) settles around the average of (0.013) among similar stocks. P/S Ratio (2.352) is also within normal values, averaging (48.960).

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 11.08B. The market cap for tickers in the group ranges from 50 to 217.6B. LIN holds the highest valuation in this group at 217.6B. The lowest valued company is JSCPY at 50.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -2%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 2%. FEAM experienced the highest price growth at 16%, while CITR experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 55
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 83
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
ALB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of specialty polymers, chemicals and related products

Industry ChemicalsSpecialty

Industry
Chemicals Specialty
Address
4250 Congress Street
Phone
+1 980 299-5700
Employees
7800
Web
https://www.albemarle.com
Interact to see
Advertisement
MRSH stock declined approximately -9% over the past 30 days, driven by sector-wide AI disruption fears and analyst downgrades. Over the past quarter, the stock fell around -7%, amid softening insurance rates and declining fiduciary interest income.
MCO stock declined approximately -9% over the last 30 days amid profit-taking, insider selling, and sector-wide concerns in financial data analytics. Over the past quarter, shares fell around -18%, reflecting a correction from January highs despite strong Q4 2025 earnings. Key drivers include post-earnings selloff after Q4 results, analyst price target cuts, and broader market volatility in credit ratings sector.
SNOW stock declined approximately -9% over the last 30 days, from around $168 to $153, amid post-earnings profit-taking and analyst caution despite strong results. Over the past quarter, the stock fell about -31%, from near $223, reflecting broader sector pressures and valuation concerns in cloud software.
WDS stock surged +24% over the past 30 days, driven by a sharp rally in oil and LNG prices amid Middle East supply disruptions, including Strait of Hormuz issues and strikes on Qatar's Ras Laffan facility. Over the past quarter, the stock climbed +55%, reflecting sustained energy market volatility and Woodside's strong production from assets like Sangomar and Pluto LNG.
HMC stock declined -19% over the past 30 days amid major setbacks in EV strategy, including cancellation of North American EV models and up to $15.7 billion in related losses. Over the past quarter, shares fell -18%, driven by persistent auto segment weakness, tariff impacts, and revised FY2026 forecasts to a net loss. Key catalysts include March EV reassessment announcement causing a 5%+ drop, Q3 earnings beat overshadowed by one-time charges and guidance concerns, and Sony-Honda JV EV project halt.
EL stock plunged approximately -39% over the past 30 days amid merger discussions with Puig, tariff pressures, and restructuring costs, marking a highly volatile period. Over the past quarter, the stock is down around -37%, reflecting broader sector headwinds despite earlier quarterly earnings beats. Key drivers include confirmation of potential business combination with Puig sparking uncertainty, ongoing $100 million tariff impacts, and elevated restructuring expenses.
ESLT stock rose +13% over the past 30 days, driven primarily by a blowout Q4 2025 earnings report with revenue up 11% and EPS beating estimates by over 10%. Over the past quarter, shares surged +52%, fueled by a record $28.1 billion order backlog, up significantly year-over-year, amid heightened global defense demand. Geopolitical tensions in the Middle East boosted demand for Elbit's systems, alongside major contract wins totaling hundreds of millions from international clients.
EQT stock rose approximately +10% over the last 30 days, driven by strong Q4 2025 earnings beat, robust free cash flow guidance for 2026, and analyst price target increases. Over the past quarter, shares gained around +23%, fueled by operational efficiencies, natural gas price recovery, and positive sector sentiment amid LNG demand growth.
Robin Energy Ltd is a Cyprus-based shipping company focused on ocean and deep-sea freight transportation. As a holding entity, it acquires, owns, charters, and manages oceangoing tanker vessels worldwide. The core of its business lies in energy transportation services, mainly through handysize tankers and LPG carriers. In the competitive marine shipping industry, RBNE positions itself as a growth-oriented player, expanding its fleet and locking in multi-year charters. Recent developments, such as vessel acquisitions and Bitcoin treasury allocations, leave it exposed to shipping cycles and alternative asset volatility. From what I see, this mix contributes to the erratic stock price behavior we've observed amid shifting global energy demand and freight rates.
NG stock plunged -42% over the past 30 days amid sharp declines from mid-March peaks around $14, driven by profit-taking after a multi-year rally and sector-wide weakness in gold mining stocks. Over the past quarter, the stock is down -14%, reflecting volatility from early-year gains tied to financing successes offset by recent macro pressures and permitting concerns. Key drivers include gold price fluctuations due to interest rate expectations, profit-taking post-240%+ annual surge, and no immediate production revenue despite Donlin Gold project advancements.
CRBU stock declined approximately -10% over the past 30 days, reflecting volatility amid clinical updates and financing concerns. Over the past quarter, the stock rose about +12%, driven by positive earnings beats and pipeline progress. Key drivers include Q4 2025 earnings beat, vispa-cel Phase 3 plans, but offset by cash burn and need for additional capital.
Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63. The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event.
SYY shares are trading approximately -6.40% lower in premarket trading on March 30, 2026, from a prior close of $81.80 to roughly $76.56. The primary catalyst is Sysco's announcement of a $29.1 billion definitive agreement to acquire Jetro Restaurant Depot, one of the nation's largest Cash & Carry food wholesalers.
Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.
FingerMotion, Inc. (FNGR) operates as a mobile data specialist, delivering mobile payment and recharge platform solutions mainly in China. The company's core revolves around telecommunication products and services, such as top-up recharges, data plans, SMS and MMS services, big data insights for consumer behavior analysis, and rich communication services (RCS) platforms. It also provides value-added products through partnerships with telecom providers and e-commerce platforms.
NIO Inc. (NIO) stands out as a leading Chinese electric vehicle manufacturer focused on premium smart EVs. The company designs, develops, and sells high-end battery electric vehicles, bolstered by its Battery-as-a-Service model that lets customers swap batteries at stations rather than owning them. In the cutthroat Chinese EV space, NIO competes directly with firms like XPEV and LI.
Xcel Energy Inc. (XEL) stands out as a major U.S. electric and natural gas utility, serving about 3.7 million electric and 2.2 million natural gas customers across eight states, mainly in the Midwest and West. The company focuses on regulated utilities, handling electricity generation, transmission, and distribution, while increasingly prioritizing renewable sources like wind and solar. Its model centers on steady, regulated returns from infrastructure investments, backed by rate cases and recovery mechanisms.
Occidental Petroleum Corporation (OXY) stands out as a leading independent energy producer, with a primary focus on hydrocarbon exploration and production. The company has significant operations in the Permian Basin, one of the U.S.'s most productive oil regions, along with assets in the Rockies, Latin America, and the Middle East. Its business model emphasizes efficient drilling, low-cost production, and carbon capture initiatives aimed at long-term sustainability.
The ProShares UltraShort Bloomberg Natural Gas (KOLD) is a leveraged inverse exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to two times the inverse (-2x) of the daily performance of the Bloomberg Natural Gas Subindex. This subindex reflects the natural gas segment of the commodities market by tracking futures contracts, primarily the second-month Henry Hub natural gas futures, weighted by liquidity and production. The fund does not invest directly in physical natural gas but uses derivatives like futures contracts and swaps to achieve its objective.
Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.
Albemarle (ALB) Stock Drops -23.75% Over 30 Days as Lithium Pressures Persist